Latest News for: esgct

Edit

Metagenomi Presents Novel, Highly Specific And Efficient Adenine Base Editors For Broad Genome Editing At ESGCT

MENA FN 24 Oct 2024
(MENAFN - GlobeNewsWire - Nasdaq) Metagenomi Adenine Base Editors (ABEs) demonstrated over 95% genome targetability Simultaneous ABE triplex editing resulted in over 95% protein knockdown in ... .
Edit

ESGCT – 2024 – Oral Presentation OR085 (Vor Biopharma Inc)

Public Technologies 24 Oct 2024
) October 24, 2024. ESGCT - 2024 - Oral Presentation OR085. CD33-CLL1 Treatment System ... Attachments Original document Permalink.
Edit

ESGCT Annual Meeting 2024 - Oral presentation (Circio Holding ASA)

Public Technologies 24 Oct 2024
). In vitro and in vivo performance of circVec. j vector-basedcircular RNA expression platform for enhanced gene therapy. Dr. Thomas Hansen, CTO. ESGCT 2024, Rome. The unique circVec expression system.. Turning the patient´s cells into circRNA factories ... 2.
Edit

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference Form 8 K (Passage Bio Inc)

Public Technologies 24 Oct 2024
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference ... Company delivered data during an oral presentation on Thursday, October 24 at ESGCT.
Edit

BBIO Canavan GTx BBP 812 – ESGCT 2024 – Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study (BridgeBio Pharma Inc)

Public Technologies 24 Oct 2024
). CANaspire Trial of Systemic AAV9-mediated Gene Therapy for Canavan Disease.. Biomarker, Imaging and Clinical Findings. Florian Eichler, MD (presenting author)1 ... Townsend1, Michael Kiefer5, Beth Leiro3, Rachel Williams3, Adam Shaywitz3, Annette Bley6.
Edit

Prime Medicine Presents In Vivo Proof of Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver Targeted LNP at ESGCT 31st Annual Congress Form 8 K (Prime Medicine Inc)

Public Technologies 24 Oct 2024
) Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress.
Edit

ArcticZymes Highlights Industry-Leading Success at ESGCT 2024 (ArcticZymes Technologies ASA)

Public Technologies 23 Oct 2024
). Dec 21, 2023. Tromsø, Norway, December 21, 2023 - ArcticZymes Technologies ASA (OSE ... Attachments Original document Permalink. Disclaimer ... (noodl.
Edit

Nvelop Therapeutics to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st ...

The Eagle-Tribune 22 Oct 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 22, 2024-- ... .
Edit

Epicrispr Biotechnologies Presents Data On Powerful Gene Reactivation With GEMS Epigenetic Editors At ESGCT

MENA FN 22 Oct 2024
(MENAFN - GlobeNewsWire - Nasdaq) – Company's non-cutting technology, engineered to be even more compact and deliverable, demonstrates synergistic gene reactivation in vitro –SOUTH SAN FRANCISCO, ... .
Edit

Meiragtx Announces Five Posters At The European Society Of Gene And Cell Therapy (ESGCT) 2024 ...

MENA FN 22 Oct 2024
(MENAFN - GlobeNewsWire - Nasdaq) Multiple Posters Highlight the Breadth of Company's Novel Genetic Medicine and Cell Therapy PlatformsLONDON and NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- MeiraGTx ... .
Edit

Generation Bio Announces The Presentation Of Preclinical Data On Ctlnp And Iqdna At The ESGCT ...

MENA FN 22 Oct 2024
(MENAFN - GlobeNewsWire - Nasdaq) New non-human primate data show highly selective in vivo delivery of mRNA to T cells with a cell-targeted lipid nanoparticle (ctLNP) CAMBRIDGE, Mass., Oct. 22, ... .
Edit

Cellectis To Present Data On TALE-Base Editors And Non-Viral Gene Therapy At The ESGCT 31St Annual Congress

MENA FN 22 Oct 2024
(MENAFN - GlobeNewsWire - Nasdaq) NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the–Company–) (Euronext Growth. ALCLS - NASDAQ. CLLS), a clinical-stage biotechnology company using its ... .
Edit

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st ...

The Eagle-Tribune 22 Oct 2024
NEW YORK, Oct ... ALCLS - NASDAQ.
Edit

Seamless Therapeutics to Present New Data at ESGCT Demonstrating its Ability to Reprogram Large Serine ...

Business Wire 22 Oct 2024
DRESDEN, Germany & LEXINGTON, Mass.--(BUSINESS WIRE)--Seamless Therapeutics today announced that it ...
Edit

Coave Therapeutics Showcases Breakthrough in Peptide-Based Conjugated AAV Vectors Using ALIGATER™ Platform in a Late-Breaking Abstract at ESGCT 2024

Pharmiweb 22 Oct 2024
... a Late-Breaking Abstract at the 2024 European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress, held in Rome, Italy ... The abstract is available to registered delegates at ESGCT Congress .

Article Search

tools

Most Viewed

×
×
×
×